{"brief_title": "A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)", "brief_summary": "This was a multicenter, prospective, 5-year surveillance study of approximately 5000 Raptiva-treated patients and approximately 500 non-Raptiva treated patients (formerly 2500 comparison patients who were treated with a biologic therapy other than Raptiva) with chronic moderate to severe plaque psoriasis who were candidates for treatment with Raptiva.", "condition": ["Psoriasis"], "study_pop": "\n      ", "sampling_method": "Probability Sample", "criteria": "Inclusion Criteria: - Have ever had a physician's diagnosis of chronic moderate to severe plaque psoriasis and be a candidate for treatment with Raptiva - Are being treated with or initiating Raptiva therapy at the time of enrollment - Be able to provide written informed consent - Be willing and able to fully to participate for the duration of patient follow-up (5 years) Exclusion Criterion: - Have previously received at least one dose of Raptiva and are not currently using or restarting treatment with Raptiva at the time of enrollment", "gender": "All", "minimum_age": "N/A", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "efalizumab", "mesh_term": ["Psoriasis"], "id": "NCT00096928"}